8,813 results match your criteria Alimentary Pharmacology and Therapeutics[Journal]


Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.

Aliment Pharmacol Ther 2019 Feb 19. Epub 2019 Feb 19.

Department of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia.

Background: Combination treatment with azathioprine for 6-12 months is the preferred strategy for starting infliximab due to improved pharmacokinetics. However, optimised infliximab monotherapy with proactive dose escalations in case of low trough levels is a safer but under-studied alternative.

Aim: To compare the clinical success and infliximab consumption of combination vs optimised monotherapy strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15179DOI Listing
February 2019

Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study.

Aliment Pharmacol Ther 2019 Feb 17. Epub 2019 Feb 17.

Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts.

Background: The older patient group with inflammatory bowel diseases (IBD) is particularly vulnerable to consequences of disease and therapy-related side effects but little is known about the best treatment options in this population.

Aim: To compare safety and efficacy of tumor necrosis factor α antagonist (anti-TNF) or vedolizumab (VDZ) in patients with IBD >60 years of age.

Methods: This retrospective study included patients with Crohn's disease (CD) or ulcerative colitis (UC) initiating anti-TNF or VDZ therapy ≥60 years of age at three study sites. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15177DOI Listing
February 2019
1 Read

Diastolic dysfunction on echocardiography does not predict survival after transjugular intrahepatic portosystemic stent-shunt in patients with cirrhosis.

Aliment Pharmacol Ther 2019 Feb 17. Epub 2019 Feb 17.

Liver Unit, Queen Elizabeth University Hospital, Birmingham, UK.

Background: Cardiac dysfunction is frequently observed in patients with cirrhosis. There remains a paucity of data from routine clinical practice regarding the role of echocardiography in the pre-assessment of transjugular intrahepatic portosystemic stent-shunt.

Aim: Our study aimed to investigate if echocardiography parameters predict outcomes after transjugular intrahepatic portosystemic stent-shunt insertion in cirrhosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15164DOI Listing
February 2019

Sex-based differences in the incidence of inflammatory bowel diseases-pooled analysis of population-based studies from the Asia-Pacific region.

Aliment Pharmacol Ther 2019 Feb 17. Epub 2019 Feb 17.

The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York City, New York.

Background: There appear to be differences in risk factor profiles for IBD between Asia-Pacific and Western populations, which might suggest idiosyncrasies in pathogenesis. Recently, sex-based differences in IBD according to the age of diagnosis have been described in Western populations.

Aim: Our primary aim was to identify whether sex-based differences in IBD incidence similarly exist across the age spectrum for Asia-Pacific populations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15178DOI Listing
February 2019
1 Read

Machine learning model to predict recurrent ulcer bleeding in patients with history of idiopathic gastroduodenal ulcer bleeding.

Aliment Pharmacol Ther 2019 Feb 13. Epub 2019 Feb 13.

Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.

Background: Patients with a history of Helicobacter pylori-negative idiopathic bleeding ulcers have an increased risk of recurring ulcer complications.

Aim: To build a machine learning model to identify patients at high risk for recurrent ulcer bleeding.

Methods: Data from a retrospective cohort of 22 854 patients (training cohort) diagnosed with peptic ulcer disease in 2007-2016 were analysed to build a model (IPU-ML) to predict recurrent ulcer bleeding. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15145DOI Listing
February 2019
1 Read
5.727 Impact Factor

A prospective study of the incidence of drug-induced liver injury by the modern volatile anaesthetics sevoflurane and desflurane.

Aliment Pharmacol Ther 2019 Feb 13. Epub 2019 Feb 13.

Melbourne Medical School, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.

Background: Volatile anaesthetics are known to cause drug-induced liver injury, a hepatotoxic reaction characterised by antibodies to trifluoroacetylated lipid and protein adducts and cytochrome p450 2E1. The incidence of volatile anaesthetic drug-induced liver injury from older agents has been described, but modern agents have not been prospectively studied.

Aim: To determine prospectively the incidence of volatile anaesthetic drug-induced liver injury from sevoflurane and desflurane. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15168DOI Listing
February 2019
2 Reads

Review article: consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis.

Aliment Pharmacol Ther 2019 Feb 13. Epub 2019 Feb 13.

Indianapolis, Indiana.

Background: The last decade has seen a rapid growth in the number of clinical trials enrolling patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (NASH). Due to the underlying chronic liver disease, patients with NASH often require different approaches to the assessment and management of suspected drug-induced liver injury (DILI) compared to patients with healthy livers. However, currently no regulatory guidelines or position papers systematically address best practices pertaining to DILI in NASH clinical trials. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/apt.15153
Publisher Site
http://dx.doi.org/10.1111/apt.15153DOI Listing
February 2019
3 Reads

Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis.

Aliment Pharmacol Ther 2019 Feb 13. Epub 2019 Feb 13.

Division of Hepatology, Department of Medicine, University of Miami, Miami, Florida.

Background: First-line treatment for autoimmune hepatitis (AIH) typically includes corticosteroids in combination with azathioprine. Mycophenolate mofetil (MMF) is often used as a rescue therapy in patients who are intolerant of, or nonresponsive to, standard therapy.

Aim: To systematically review studies and perform a meta-analysis on the efficacy and safety of MMF as a second-line therapy for AIH patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15157DOI Listing
February 2019

Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia.

Aliment Pharmacol Ther 2019 Feb 13. Epub 2019 Feb 13.

Washington, District of Columbia.

Background: Although the prevalence of extrahepatic manifestations of chronic hepatitis C virus (HCV) infection has been reported from Western countries, their prevalence in East Asian countries is not well known.

Aim: To perform a systematic review to quantify the prevalence of selected extrahepatic manifestations of HCV among patients from East Asia.

Methods: Medline, CINAHL, EMBASE, Cochrane and country-specific databases were reviewed according to standard guidelines for meta-analyses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15131DOI Listing
February 2019
2 Reads

Review article: iron disturbances in chronic liver diseases other than haemochromatosis - pathogenic, prognostic, and therapeutic implications.

Authors:
Albert J Czaja

Aliment Pharmacol Ther 2019 Feb 13. Epub 2019 Feb 13.

Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.

Background: Disturbances in iron regulation have been described in diverse chronic liver diseases other than hereditary haemochromatosis, and iron toxicity may worsen liver injury and outcome.

Aims: To describe manifestations and consequences of iron dysregulation in chronic liver diseases apart from hereditary haemochromatosis and to encourage investigations that clarify pathogenic mechanisms, define risk thresholds for iron toxicity, and direct management METHODS: English abstracts were identified in PubMed by multiple search terms. Full length articles were selected for review, and secondary and tertiary bibliographies were developed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15173DOI Listing
February 2019
1 Read

Editorial: redrawing the boundaries for surgical intervention in hepatocellular carcinoma-authors' reply.

Aliment Pharmacol Ther 2019 Mar;49(5):616-617

Hepatopancreatobiliary Surgery Department I, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15142DOI Listing

Review article: dietary fibre in the era of microbiome science.

Aliment Pharmacol Ther 2019 Mar;49(5):506-515

APC Microbiome Ireland, University College Cork, National University of Ireland, Cork, Ireland.

Background: Explanations for the health benefits of dietary fibre have, in the past, been inconsistent and studies of the physiological effects of dietary fibre were, perhaps, directed at the wrong read-outs. Confounding factors included a failure to appreciate the molecular diversity and varied properties of fibre-types and the role of fibre as a substrate for microbial metabolism in the gut.

Aim: To present a modern perspective on fibre science and to encourage clinicians to re-consider the health impact of dietary fibre and how best to approach adjustments in dietary consumption. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/apt.15129
Publisher Site
http://dx.doi.org/10.1111/apt.15129DOI Listing
March 2019
3 Reads

Editorial: identifying candidates for pegylated interferon add-on to entecavir therapy in patients with HBeAg-positive chronic hepatitis B.

Authors:
Cheng-Yuan Peng

Aliment Pharmacol Ther 2019 Mar;49(5):609-610

Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15136DOI Listing
March 2019
1 Read

Editorial: redrawing the boundaries for surgical intervention in hepatocellular carcinoma.

Aliment Pharmacol Ther 2019 Mar;49(5):614-615

Department of Surgery, Royal Infirmary of Edinburgh, Edinburgh, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15121DOI Listing
March 2019
1 Read

Letter: anxiety after coeliac disease diagnosis predicts mucosal healing-a population-based study.

Aliment Pharmacol Ther 2019 Mar;49(5):619

Department of Gastroenterology, Lanstinghet Gävleborg, Region Gävleborg, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15110DOI Listing
March 2019
1 Read

Editorial: simplifying screening for primary liver cancer - do the LCR1 and LCR2 tests hold the key?

Aliment Pharmacol Ther 2019 Mar;49(5):612-613

Cancer Research UK Beatson Institute, Glasgow, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15119DOI Listing
March 2019
1 Read

Editorial: identifying candidates for pegylated interferon add-on to entecavir therapy in patients with HBeAg-positive chronic hepatitis B - authors' reply.

Aliment Pharmacol Ther 2019 Mar;49(5):610-611

Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15155DOI Listing
March 2019
2 Reads

Editorial: is cirrhosis depressing?

Aliment Pharmacol Ther 2019 Mar;49(5):611-612

Department of Psychological Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15115DOI Listing
March 2019
1 Read

Editorial: quality of life and mortality in cirrhosis and ascites.

Authors:
Ronan O'Carroll

Aliment Pharmacol Ther 2019 Mar;49(5):617-618

Psychology, University of Stirling, Stirling, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15122DOI Listing
March 2019
2 Reads

Letter: anxiety after coeliac disease diagnosis predicts mucosal healing-a population-based study. Authors' reply.

Aliment Pharmacol Ther 2019 Mar;49(5):620

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15130DOI Listing

Editorial: simplifying screening for primary liver cancer - do the LCR1 and LCR2 tests hold the key? Authors' reply.

Aliment Pharmacol Ther 2019 Mar;49(5):613-614

INSERM, Saint-Antoine Research Center & Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne Université, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15135DOI Listing
March 2019
1 Read

Bile and fat excretion are biomarkers of clinically significant diarrhoea and constipation in irritable bowel syndrome.

Aliment Pharmacol Ther 2019 Feb 10. Epub 2019 Feb 10.

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

Background: Biomarkers in irritable bowel syndrome (IBS) may guide targeted therapy in this multifactorial disease. It has been suggested that 75% accuracy and cost <$500 categorise biomarkers as cost-effective.

Aim: To identify differences in faecal bile acids, faecal fat and fasting serum C4 (7a-hydroxy-4-cholesten-3-one) and fibroblast growth factor 19 (FGF19) among patients with IBS-D, IBS-C and healthy controls and to determine accurate, cost-effective biomarkers for clinically relevant diarrhoea and constipation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15106DOI Listing
February 2019
2 Reads

Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro-oesophageal reflux-induced chronic cough.

Aliment Pharmacol Ther 2019 Feb 10. Epub 2019 Feb 10.

Department of Pulmonary and Critical Care Medicine, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.

Background: Neuromodulators are considered potential therapeutic options for refractory gastro-oesophageal reflux-induced chronic cough.

Aim: To compare the efficacy of gabapentin and baclofen in patients with suspected refractory gastro-oesophageal reflux-induced chronic cough.

Methods: Two hundred and thirty-four patients with suspected refractory gastro-oesophageal reflux-induced chronic cough, who failed an 8-week course of omeprazole and domperidone, were recruited into the open-labelled study and randomly assigned to receive either gabapentin (maximum daily dose of 900 mg) or baclofen (maximum daily dose of 60 mg) for 8 weeks as add-on therapy to the previous treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15169DOI Listing
February 2019
5.727 Impact Factor

Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation.

Aliment Pharmacol Ther 2019 Feb 10. Epub 2019 Feb 10.

Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands.

Background: After liver transplantation primary sclerosing cholangitis (PSC), the condition returns in the transplanted liver in a subset of patients (recurrent primary sclerosing cholangitis, rPSC).

Aim: To define risk factors for rPSC.

Methods: We searched Pubmed, Embase, Web of Science, and Cochrane library for articles published until March 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15148DOI Listing
February 2019
2 Reads

Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease.

Aliment Pharmacol Ther 2019 Feb 8. Epub 2019 Feb 8.

Department of Gastroenterology, University Hospitals Birmingham, Birmingham, UK.

Background: Biological therapy is currently widely used to treat IBD. Infliximab, adalimumab and golimumab are currently licensed anti-TNF therapies. Biosimilar anti-TNF monoclonal antibodies are increasingly used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15097DOI Listing
February 2019
1 Read

Systematic review and meta-analysis: the prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease.

Aliment Pharmacol Ther 2019 Feb 8. Epub 2019 Feb 8.

The University of Queensland, Faculty of Medicine and Faculty of Health and Behavioural Sciences, Brisbane, QLD, Australia.

Background: Current data on small intestinal bacterial overgrowth (SIBO) in patients with inflammatory bowel diseases (IBD) are controversial.

Aim: To conduct a systematic review and meta-analysis to determine the prevalence of SIBO in patients with ulcerative colitis (UC) and Crohn's disease (CD).

Methods: Electronic databases were searched up to May 2018 for studies reporting prevalence of SIBO in IBD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15133DOI Listing
February 2019
2 Reads

Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease.

Aliment Pharmacol Ther 2019 Feb 7. Epub 2019 Feb 7.

Division of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, P.R. China.

Background: Owing to the importance of early treatment, simple and reliable methods for monitoring inflammatory bowel disease (IBD) are needed.

Aims: To determine whether circulating microRNAs are reliable biomarkers for IBD monitoring.

Methods: Serum levels of 17 candidate microRNAs were measured by quantitative real-time polymerase chain reaction in a discovery cohort (n = 120). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15159DOI Listing
February 2019
3 Reads
5.727 Impact Factor

Review article: shared disease mechanisms between non-alcoholic fatty liver disease and metabolic syndrome - translating knowledge from systems biology to the bedside.

Aliment Pharmacol Ther 2019 Mar 4;49(5):516-527. Epub 2019 Feb 4.

School of Medicine, Institute of Medical Research A. Lanari, University of Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina.

Background: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease worldwide. Characterised by abnormal fat accumulation in the liver, NAFLD presents high degree of comorbidity with disorders of the metabolic syndrome, including type 2 diabetes, obesity and cardiovascular disease. These comorbidities have strong negative impact on the natural course of NAFLD and vice versa, whereby the presence of NAFLD substantially modifies the course and prognosis of metabolic syndrome-associated diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15163DOI Listing
March 2019
2 Reads

Body mass index in early pregnancy and future risk of severe liver disease: a population-based cohort study.

Aliment Pharmacol Ther 2019 Feb 3. Epub 2019 Feb 3.

Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.

Background: In young men, high body mass index (BMI) has been linked to liver disease later in life, but it is unclear if this also applies to women.

Aim: To study the association between BMI early in life and development of liver disease later in life in women.

Methods: We obtained data on early pregnancy BMI from 1 139 458 Swedish women between 1992 and 2015. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/apt.15162
Publisher Site
http://dx.doi.org/10.1111/apt.15162DOI Listing
February 2019
3 Reads

The evolution and impact of sarcopenia pre- and post-liver transplantation.

Aliment Pharmacol Ther 2019 Feb 3. Epub 2019 Feb 3.

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Background: Sarcopenia is associated with both increased wait-list mortality and mortality following liver transplantation.

Aims: To determine the course of sarcopenia from transplant evaluation until 1 year post-transplant, and its implications on hospitalisation and mortality following liver transplantation.

Methods: Two hundred and ninety-three transplant recipients from 2002 to 2006 had pre-transplant CT scans analysed at the third lumbar region for sarcopenia, myosteatosis and abdominal visceral fat content. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15161DOI Listing
February 2019
2 Reads

Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers.

Aliment Pharmacol Ther 2019 Jan 31. Epub 2019 Jan 31.

Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.

Background: Evaluation of the metabolomic profile of patients with irritable bowel syndrome offers an opportunity to identify novel pathophysiological targets and biomarkers that could discriminate this disorder from related conditions.

Aim: To identify potential urinary biomarkers that discriminate irritable bowel syndrome patients from ulcerative colitis patients in remission and healthy controls and to explore the pathophysiology of irritable bowel syndrome using a metabolomic approach.

Methods: Urine samples were collected from 39 irritable bowel syndrome patients, 53 ulcerative colitis patients in clinical remission and 21 healthy controls. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/apt.15141
Publisher Site
http://dx.doi.org/10.1111/apt.15141DOI Listing
January 2019
5 Reads

Systematic review with meta-analysis: cholecystectomy for biliary dyskinesia-what can the gallbladder ejection fraction tell us?

Aliment Pharmacol Ther 2019 Jan 31. Epub 2019 Jan 31.

Gastroenterology and Hepatology, Lynda K and David M Underwood Center for Digestive Disorders, Houston Methodist Hospital and Weill Cornell Medical College, Houston, Texas.

Background: Gallbladder dyskinesia (gallbladder spasm, biliary dyskinesia or chronic acalculous cholecystitis) is a poorly defined entity which presents as biliary-type pain without any identifiable organic pathology. Abnormal gallbladder ejection fraction (GBEF) is used by some to select those likely to benefit from cholecystectomy. The validity of this approach has been questioned. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15128DOI Listing
January 2019
2 Reads
5.727 Impact Factor

Mechanisms underlying effects of kiwifruit on intestinal function shown by MRI in healthy volunteers.

Aliment Pharmacol Ther 2019 Jan 31. Epub 2019 Jan 31.

National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK.

Background: Chronic constipation affects approximately 17% of the population worldwide and remains an important unmet need since patients are often dissatisfied with treatment. Kiwifruit may offer an alternative to traditional laxatives and have been shown to increase stool volume, frequency and improve consistency.

Aims: Using non-invasive MRI techniques, we assessed the effect of ingestion of kiwifruit on fluid distribution in the intestines and bowel function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15127DOI Listing
January 2019

Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib.

Aliment Pharmacol Ther 2019 Mar 29;49(5):482-491. Epub 2019 Jan 29.

Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clínic de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad de Barcelona, Barcelona, Spain.

Background: The positive results of the REFLECT trial in terms of survival (sorafenib vs lenvatinib) offer a new first-line option for hepatocellular carcinoma. Additionally, the expected results of immunotherapy could change the first-line treatment in hepatocellular carcinoma or the clinical trial design in first and second-line.

Aims: To evaluate the impact of dermatologic adverse events under sorafenib in hepatocellular carcinoma patients as a clinical marker to predict prognosis and critically evaluate outcomes within trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15088DOI Listing

Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B.

Aliment Pharmacol Ther 2019 Feb;49(4):448-456

Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.

Background: Various treatment combinations of peginterferon (PEG-IFN) and nucleos(t)ide analogues have been evaluated for chronic hepatitis B (CHB), but the optimal regimen remains unclear.

Aims: To study whether PEG-IFN add-on increases response compared to entecavir (ETV) monotherapy, and whether the duration of ETV pretreatment influences response.

Methods: Response was evaluated in HBeAg positive patients previously treated in two randomized controlled trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15098DOI Listing
February 2019
2 Reads

Editorial: raising the bar on probiotic foods.

Aliment Pharmacol Ther 2019 Feb;49(4):474-475

National University Singapore Yong Loo Lin School of Medicine, Singapore, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15117DOI Listing
February 2019

Editorial: liver transplantation for primary biliary cholangitis-the need for timely and more effective treatments.

Aliment Pharmacol Ther 2019 Feb;49(4):472-473

Division of Gastroenterology and Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15095DOI Listing
February 2019
2 Reads

Editorial: liver transplantation for primary biliary cholangitis-the need for timely and more effective treatments. Authors' reply.

Aliment Pharmacol Ther 2019 Feb;49(4):473-474

Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15118DOI Listing
February 2019
2 Reads

Letter: impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease - authors' reply.

Aliment Pharmacol Ther 2019 Feb;49(4):477-478

Gastroenterology, Hospital Universitario Central de Asturias, Oviedo, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15125DOI Listing
February 2019

Population based study: atopy and autoimmune diseases are associated with functional dyspepsia and irritable bowel syndrome, independent of psychological distress.

Aliment Pharmacol Ther 2019 Mar 27;49(5):546-555. Epub 2019 Jan 27.

Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW, Australia.

Background: The pathogenesis of functional GI disorders (FGIDs) is uncertain. However, underlying immune activation and psychological distress has been documented in irritable bowel syndrome (IBS) and functional dyspepsia (FD). Epidemiological data from the UK suggest that FGIDs are linked to atopy and certain autoimmune diseases but this has not been confirmed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15120DOI Listing
March 2019
3 Reads

Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis.

Aliment Pharmacol Ther 2019 Jan 27. Epub 2019 Jan 27.

Department of Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany.

Background: Primary sclerosing cholangitis is associated with an increased risk of biliary tract cancer. Carbohydrate antigen 19-9 (CA19-9) can be used to screen for these malignancies.

Aim: To perform a longitudinal analysis of CA19-9 in patients with primary sclerosing cholangitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15146DOI Listing
January 2019
1 Read

Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection.

Aliment Pharmacol Ther 2019 Mar 27;49(5):492-505. Epub 2019 Jan 27.

Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Background: Hepatitis C virus (HCV) genotype 6 (GT6) is predominantly encountered in Southeast Asia and data on GT6 response to direct-acting antiviral (DAA) therapy are relatively limited.

Aim: To review the epidemiology and virologic outcome of DAA regimens in HCV GT6 patients.

Methods: Electronic literature search of PubMed, EMBASE, and The Cochrane Library databases were conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15100DOI Listing

Trends in the epidemiology of inflammatory bowel disease among Jewish Israeli adolescents: a population-based study.

Aliment Pharmacol Ther 2019 Mar 27;49(5):556-563. Epub 2019 Jan 27.

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Background: The incidence and prevalence trends of inflammatory bowel disease (IBD) vary between developed and developing countries.

Aim: To investigate the prevalence and associated sociodemographic factors of IBD in Israeli Jewish adolescents METHODS: The files of the army medical corps were reviewed for adolescents recruited in 2002-2016 with confirmed IBD. Covariate data included birth date, patient and parental country of birth, number of children in the household, age at diagnosis, and socioeconomic status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15160DOI Listing
March 2019
1 Read

Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma.

Aliment Pharmacol Ther 2019 Mar 25;49(5):589-598. Epub 2019 Jan 25.

Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Background: Chronic hepatitis B has been linked to lymphoma with contradictory results.

Aim: To investigate the association between chronic hepatitis B and lymphoma by using a nationwide population-based cohort.

Methods: Records of patients diagnosed with chronic hepatitis B (hepatitis B virus [HBV] cohort) or without (non-HBV cohort) during 2004-2007 were retrieved from the Taiwan National Health Insurance Research Database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15132DOI Listing
March 2019
1 Read

Nonselective beta-blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study.

Aliment Pharmacol Ther 2019 Mar 22;49(5):582-588. Epub 2019 Jan 22.

Clichy, France.

Background: Nonmalignant portal vein thrombosis is a significant event in the course of cirrhosis that can contraindicate liver transplantation and even impact survival after the surgical procedure. Risk factors are not completely known or validated and are still debated.

Aim: To identify in patients with cirrhosis the risk factors for portal vein thrombosis that are assessable in clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15137DOI Listing
March 2019
2 Reads

Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop.

Aliment Pharmacol Ther 2019 Mar 22;49(5):528-536. Epub 2019 Jan 22.

Hamburg, Germany.

Background: Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease that results in substantial morbidity and mortality with many unanswered clinical and research questions. Improved understanding of disease pathogenesis, including the extra-hepatic manifestations of AIH, may allow targeted treatments with greater efficacy and fewer associated adverse events.

Aim: To identify the spectrum of unanswered clinical and research questions facing care providers in the management of patients with autoimmune hepatitis (AIH). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/apt.15111
Publisher Site
http://dx.doi.org/10.1111/apt.15111DOI Listing
March 2019
6 Reads

Letter: different risks of venous thromboembolism in subsets of patients with inflammatory bowel diseases.

Aliment Pharmacol Ther 2019 Feb;49(3):345-346

Department of Cardiology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15083DOI Listing
February 2019
2 Reads

Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study.

Aliment Pharmacol Ther 2019 Feb;49(3):265-276

Inflammation & Immunology, Pfizer Inc, Collegeville, Pennsylvania.

Background: Tofacitinib is an oral, small molecule Janus kinase inhibitor that is being investigated for inflammatory bowel disease.

Aims: This 48-week open-label extension study primarily investigated long-term safety of tofacitinib 5 and 10 mg b.d. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15072DOI Listing
February 2019
6 Reads

Editorial: the role of vitamin D in autoimmune hepatitis-authors' reply.

Aliment Pharmacol Ther 2019 Feb;49(3):343-344

Division of Gastroenterology & Liver Unit, University of Alberta Hospital, Edmonton, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15091DOI Listing
February 2019
2 Reads